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Abstract The paper describes an application of a re-
cently developed machine learning technique called Mon-
drian predictors to risk assessment of ovarian and breast
cancers. The analysis is based on mass spectrometry
profiling of human serum samples that were collected
in the United Kingdom Collaborative Trial of Ovar-
ian Cancer Screening. The paper describes the tech-
nique and presents the results of classification (diag-
nosis) and the corresponding measures of confidence of
the diagnostics. The main advantage of this approach
is a proven validity of prediction. The paper also de-
scribes an approach to improve early diagnosis of ovar-
ian and breast cancers since the data in the United
Kingdom Collaborative Trial of Ovarian Cancer Screen-
ing were collected over a period of seven years and do
allow to make observations of changes in human serum
over that period of time. Significance of improvement is
confirmed statistically (for up to 11 months for Ovarian
Cancer and 9 months for Breast Cancer). In addition,
the methodology allowed us to pinpoint the same mass
spectrometry peaks as previously detected as carrying
statistically significant information for discrimination
between healthy and diseased patients. The results are
discussed.
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1 Introduction
Recent advances in the analysis of the human serum
proteome aim to establish novel disease biomarkers that
would allow early detection of diseases. The current
techniques include analysis of serum using mass spec-
trometry (MS). The output of MS is a large volume of
high-dimensional data (Fig. 1), and it requires modern
methods of data analysis. Several powerful methods of
analysis of high-dimensional data have been developed.
Among them are the SVM and other kernel techniques
that are usually good in accuracy of classification (di-
agnosis) but suffer from a lack of a measure of confi-
dence in the diagnosis; therefore, it is difficult to esti-
mate risk of incorrect diagnosis of a patient. This pa-
per describes a novel machine learning technique called
Mondrian predictors1, also known as Category-based
Confidence Machines, that addresses this problem by
introducing measures of confidence that would allow us
to estimate a risk of misclassification. The Mondrian
predictors were applied to a subset of the United King-
dom Collaborative Trial of Ovarian Cancer Screening
(UKCTOCS) biobank which contains serum samples
and data on cancers in a cohort of 202,638 women
participating in this trial. Women were recruited be-
tween 2001 and 2005, and those in the cancer anti-
gen 125 (CA125) screening (multimodal) group under-
went annual screening with repeat samples collected if
an abnormality was detected2. Women were followed
up through cancer registry and postal questionnaires.
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Fig. 1 Example of a spectrum with identified peaks
The unique feature of this trial was that the women
were screened annually for up to 5 years. Two case
control sets of samples from women diagnosed to have
ovarian and breast cancer respectively and healthy (no
cancer at follow up) controls were undertaken. Control
samples were matched for trial centres and date when
the cancer sample was taken to minimise differences in
sample processing. The serum samples underwent pre-
fractionation using a reversed-phase batch extraction
protocol prior to MALDI-TOF MS data acquisition3,4.
In this paper, we analysed ovarian cancer and breast
cancer data sets.
In this work we base on the theory of hedged (con-
fident) algorithmic learning1. One of the major advan-
tages of hedged algorithms is that they can be used
for solving high-dimensional problems without requir-
ing any parametric statistical assumptions about the
source of data (unlike traditional statistical techniques);
the only assumption made is the i.i.d.: the examples are
generated from the same probability distribution inde-
pendently of each other. Another advantage of confor-
mal predictor is that it also allows to make estimation of
confidence in the classification of individual examples.
The algorithm itself is based on testing each classi-
fication hypothesis abouta new example whether it is
conforms i.i.d. assumption. This requires application of
a test for randomness based on a non-conformity mea-
sure (NCM) which is a way of ranking objects within a
set by their relative strangeness. The defining property
of NCM is its independence of the order of examples,
so any computable functions with this property can be
used. Conformal predictor is valid under any choice of
NCM, however it can be more efficient if NCM is ap-
propriate. Concrete meaning of efficiency (performance
measure) depends on the problem type and interpreta-
tion of output.
NCM for classification is also usually based on an
underlying learning algorithm. For example, it can be k-
Nearest-Neighbours (kNN) algorithm. Although is usu-
ally applied to clean data, where all attributes are in-
formative (such as USPS handwritten digits14), with
an additional step of feature selection it may be used
in less clean cases, for example in the work on Machine
Learning in Functional Clustering15, where only few
attributes (gene expressions) are useful for separation
between diseases, we embedded a step of feature selec-
tion (based on a T-test) into a version of kNN NCM.
Another useful underlying algorithm is Support Vec-
tor Machine (SVM)16,17. In the work on diagnostic us-
ing microarrays18 an SVM-based NCM was used to-
gether with another NCM based on Nearest Centroid
that is in some sense a ’limit’ version of Nearest Neigh-
bours..
However, NCM for some special data are not di-
rectly based on standard underlying algorithms: in the
work19 we apply algorithm where ’conformity’ between
a set and a new example represented by a number of
attributes (voxels) showing good separability, e.g. by
two-sample T-test.
We are now working with Mass Spectrometry that
has its own specific as well. Although it is high-dimensional
(many peaks are identified), we know from the practice
that normally only few of them (called biomarkers) re-
act to the disease. Thus we developed a version of con-
formal predictor with a special NCM that is based on
a search within a high-dimensional data for a simple
decision rule that involves only few biomarkers.
This paper first outlines the background and intro-
duces the main ideas of conformal predictors and its ex-
tension to Mondrian predictors. We then describe the
data and classification rules and present the results.
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2 Methods
The framework we are going to deploy in the analysis
of MS data is the one of conformal predictors1,5. It rep-
resents a new generation of algorithms with reliability
measures.
2.1 Conformal Predictors
Let us assume that we are given a training set of pa-
tients with diagnoses
(x1, y1), . . . , (xn−1, yn−1)
where xi ∈ X is a vector of features which describe
a patient and yi ∈ Y is a diagnosis out of a finite
set of possible diagnoses (classes). Our goal is to pre-
dict the diagnosis yn for a new patient xn. We will
denote a combination of a patient and a diagnosis as
zi = (xi, yi) ∈ Z = X × Y .
The general idea of conformal predictors is the fol-
lowing: when we have a new patient, xn, we try every
possible diagnosis y as a candidate for patient’s diagno-
sis and see how well the resulting pair (xn, y) conforms
with (x1, y1), . . . , (xn−1, yn−1). The ideal case is when
exactly one diagnosis conforms with the rest of the se-
quence and all others do not. We can then be confident
in predicting this diagnosis.
Firstly, we need to define the notion of a nonconfor-
mity measure, which is the core of conformal predictors.
A specific nonconformity measure depends on a partic-
ular algorithm and can be based on many well-known
machine learning algorithms. This nonconformity mea-
sure will assign some value αi (nonconformity score)
to every patient in the sequence z1, . . . , zn including a
new patient with diagnosis and will evaluate ‘noncon-
formity’ between a set and its element:
αi := An(Hz1, . . . , zi−1, zi+1, . . . , znI, zi), i = 1, . . . , n ,
(1)
where H. . .I denotes a multiset.
When we consider a diagnosis hypothesis yn = y
and after we calculated the corresponding nonconfor-
mity scores α1, . . . , αn for a full sequence with diagno-
sis y for the last patient, a natural way to compare αn
with the other αis is to look at the ratio of patients
which conform with the the other patients at most as
much as the new one, that is, to calculate
pn(y) =
|{i = 1, . . . , n− 1 : αi ≥ αn}|+ 1
n
. (2)
This ratio is called the p-value associated with the
possible diagnosis y for xn. Thus, we can complement
each candidate diagnosis with a p-value, which shows
how well a new patient with this possible diagnosis con-
forms with the rest of the sequence in comparison with
other patients. The last thing which needs to be set is
a significance level 0 <  < 1, which is an error rate we
are willing to tolerate.
Finally, the p-values calculated above can produce
a region predictor: the conformal predictor determined
by the nonconformity measure An, n = 1, 2, . . ., and
a significance level  is defined as the function Γ :
Z∗ × X × (0, 1) → 2Y (2Y is the set of all subsets of
Y ) such that the prediction set Γ ()(x1, y1, . . . , xn−1,
yn−1, xn) is defined as the set of all candidate diag-
noses y ∈ Y such that pn(y) > . Thus, for any finite
sequence of diagnosed patients, (x1, y1, . . . , xn−1, yn−1),
a new undiagnosed patient xn and a significance level
, the conformal predictor outputs a region prediction
Γ () — a set of possible diagnoses for the new patient.
The main advantage of conformal predictors is their
validity : in the long run the frequency of errors made
by a conformal predictor (i.e., cases when prediction set
Γ  does not contain the real diagnosis) does not exceed
 (this is subject to the assumption that all examples
are drawn independently from the same distribution,
which is called the i.i.d. assumption). This point is dif-
ferent from the methods (such as logistic regression)
which produce probabilistic estimates that rely on as-
sumptions that are stronger than i.i.d.
While validity is guaranteed, we have to optimize
efficiency — the ability of conformal predictors to pro-
duce as small region predictions as possible.
2.1.1 Alternative Way of Presenting the Results
However, prediction sets are dependent on selected sig-
nificance level . If there are several such levels, predic-
tion sets form a nested sequence: prediction set for a
smaller  always covers a prediction set for a larger . If
Y is finite, we can summarize all these outputs in one.
It is enough to order all possible labels by their p-values
and to set thresholds for  at which the cardinality of
prediction set changes. If Y is binary, this is the same as
to output a prediction for each example by choosing the
highest p-value and to complement each such prediction
with two indicators: confidence and credibility. Confi-
dence is equal to 1 less the second maximum p-value,
it is the complement to 1 of the smallest  at which the
prediction set is certain (contains of at most one ele-
ment). Credibility is the maximum value of all possible
p-values, or the smallest  at which the prediction set
is empty.
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High confidence means that the alternative diag-
noses are excluded by having a low p-value, high credi-
bility checks whether the prediction itself does not have
too small a p-value. Thus, a prediction is considered to
be reliable if its confidence is close to 1 and its cred-
ibility is not close to 0. If its credibility is low, this
means that the new patient is not typical for any class
presented in the training set.
2.2 Mondrian Predictors
Conformal predictors allow us to obtain a guaranteed
error rate which does not exceed the significance level
. However, we may encounter problems in medical di-
agnosis, when we know that certain patients are easier
to correctly classify than others (for example, men are
more easily diagnosed than women, or it is more likely
to misclassify a healthy patient than a diseased one). In
this case, conformal predictors will guarantee the over-
all error rate; however, they may result in higher actual
error rate on harder groups of patients and lower on
easier groups of patients. However, it would be good to
guarantee the error rate within these groups.
Mondrian predictors1,5, which are the development
of conformal predictors, allow us to tackle this problem.
They split all possible patients into categories and set
significance levels k, one for each category k. Mondrian
predictors can guarantee that in the long run patients
of each category k are misclassified with frequency at
most k.
One of the simplest examples could be a taxonomy
conditioned on diagnoses, when each category corre-
sponds to a certain diagnosis and comprises only pa-
tients with this diagnosis. Another possibility is divi-
sion in categories based on features and their combi-
nations: e.g., patients can be grouped by age. Finally,
taxonomies can get even more complex: they can be
based on combinations of features, diagnoses and even
ordinal numbers of patients in the sequence.
In comparison with conformal predictors, the dif-
ference in constructing Mondrian predictors is that we
compare the non-conformity score of (xn, y) not with
all patients in the sequence but only with patients of
the same category:
pn(y) =
|{i = 1, . . . , n− 1 : κi = κn & αi ≥ αn}|+ 1
|{i = 1, . . . , n− 1 : κi = κn}|+ 1 ,
(3)
where κi, i = 1, . . . , n− 1 is the category of (xi, yi); κn
is a category of (xn, y).
Finally, any Mondrian predictor is conditionally valid :
in the long run the frequency of errors made by the ma-
chine (i.e., cases when prediction set does not contain a
real diagnosis) on patients in category k does not exceed
k for each k.
Thus, Mondrian predictors allow us to solve two
main problems.
– We can guarantee not only an overall accuracy but
also a certain level of accuracy within each category
of patients. In particular, we can preset the level
of accuracy within groups of healthy and diseased
samples, which is similar to specificity and sensi-
tivity. This will allow avoiding classifications when
small number of errors on healthy samples is com-
pensated by high number of errors on diseased ones
or the other way around. Therefore we use Mondrian
predictors.
– If we preset different significance levels for cate-
gories, we can treat them in a different way: e.g.,
put analogue of sensitivity first and consider a mis-
classification of a diseased sample more serious than
misclassification of a healthy sample.
3 Data
The methodology based on a Mondrian predictor was
applied to the data sets from the UKCTOCS study,
which was designed to provide data on the effect of
ovarian cancer screening on mortality. It is the world’s
largest ovarian cancer screening research programme
and involves sample collection of 200,000 women aged
50–74 years. In this research, we have analysed available
ovarian cancer and breast cancer data sets.
The data pertain to serum samples collected from
patients diagnosed with the disease (we will call them
cases) and healthy patients (they will be referred to
as controls). Originally, each case was accompanied by
two controls matched on patient age, sample collection
location and sample collection date/time, among other
factors. For this reason, in each data set the number of
controls is twice as large as the number of cases:
– 104 cases and 208 controls in the ovarian cancer data
set (312 samples in total);
– 54 cases and 108 controls in the breast cancer data
set (162 samples in total).
The samples were analysed by MS and its output by
the use of a Mondrian predictor. The MS data of ovar-
ian and breast cancers were provided by the University
of Reading and University College London, respectively.
MS is an attractive analytical tool because it en-
ables researchers to simultaneously analyse hundreds
of biomolecules. MALDI-TOF (Matrix Assisted Laser
Desorption/Ionisation—Time of Flight) MS, one of sev-
eral possible techniques, has revealed the complexity
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of the low-molecular weight proteomes of serum and
plasma.
The MS data we have submitted to our methodology
are represented as intensities at m/z (mass to charge
ratio) values. Preprocessing steps, including peak iden-
tification, applied in this work can be found in a sep-
arate paper8. The identified peaks are sorted by their
frequency: the greater the number of mass spectra con-
taining a peak, the higher is the rank of that peak. We
consider a certain number of the most frequent peaks
only. Throughout the article, peak numbers are used;
the lower the peak number, the more common the peak
is. Please note that sets of peaks vary for different data
sets, therefore peaks with the same number from vari-
ous data sets have different m/z-values.
Several biomarkers for ovarian cancer have been iden-
tified, but none so far have been adopted for screening.
The most extensively assessed biomarker is CA125 that
is typically elevated in the blood of some ovarian cancer
patients. However, the potential role of this protein for
the early detection of ovarian cancer is unproven and
still subject to clinical trials. One of the main prob-
lems related to the use of CA125 is its low predictive
ability at early-stages of the disease. Another problem
is that CA125 can be produced by other mesothelium-
derived tissues8 and therefore may also be elevated in
women with benign gynaecological conditions and other
types of cancer (such as breast, bladder, pancreatic,
liver, lung)9. Therefore, CA125 deployment lacks sensi-
tivity: if the level of CA125 is elevated, an operation is
needed to confirm the disease. Thus, it is thought that
CA125 alone may not be accurate enough for detection
of early-stage ovarian cancer.
In this study we aim to verify whether it is pos-
sible to improve the ability of CA125 to discriminate
between ovarian cancer and healthy patients in early
stages of the disease. Also, we attempt to identify cer-
tain mass spectral peaks which could, in combination
with CA125, result in accurate ovarian cancer diagnosis
well in advance of the moment of clinical diagnosis.
Thus, each mass spectrum of the ovarian cancer
data set is also assigned a level of CA125, and we will
make predictions of the diagnosis based not only on
MALDI-TOF MS data but also on CA125 levels.
Finally, each sample is assigned a non-negative value
T (τ) — time to diagnosis confirmed by histology/cytology.
Controls are assigned the same value T (τ) as the case
they match. We will refer to this value as time to di-
agnosis and the moment of diagnosis confirmed by his-
tology/cytology as the moment of diagnosis. Since we
have the information regarding when each sample was
taken, we can consider sets of samples taken in different
time slots before the moment of diagnosis.
4 Algorithms
Practically any known machine learning algorithm can
be plugged into a Mondrian predictor and thus result
in a new algorithm of prediction with confidence. In our
research, we used a set of linear discriminant functions.
This section describes the application of linear rules
within the framework of Mondrian predictors used for
discrimination between MS samples taken from healthy
and diseased patients.
Every patient description, xi, comprises M features
xi(q), q = 1, . . . ,M . In the case of the breast cancer
data, these features are intensities of the M most fre-
quent peaks xi(q) = I(q), q = 1, . . . ,M . For the ovarian
cancer data, the features are the (M−1) most frequent
peaks and biomarker CA125 xi(M) = Ci. Diagnoses,
yi, are equal to 0 for controls and 1 for cases.
When designing a new Mondrian predictor we will
use simple linear rules of the following type (see Algo-
rithm 1):
m∑
k=1
vk log I(qk) > θ , (4)
where m is a fixed (usually small) number of peaks in
a linear combination, I(qk) is the intensity of peak qk;
vk ∈ R; k = 1, . . . ,m are weights; θ ∈ R is a threshold.
A rule classifies a patient as diseased if it returns the
value true, healthy otherwise.
In order to design a nonconformity measure, we first
need to define the taxonomy of a Mondrian predictor.
We will consider the taxonomy κ(n, (xn, yn)) = yn,
i.e., the taxonomy which consists of two categories that
correspond to two different diagnoses: the category of
healthy patients and the category of diseased patients.
Such taxonomy will allow us to guarantee the error rate
within classes of healthy patients and diseased patients,
which is analogous to controlling sensitivity and speci-
ficity. Hence, p-values are calculated as in equation 3
with ki = yi. i.e., the p-value is calculated as the ratio
of healthy (diseased) patients which conform with the
the other patients at most as much as the new one to
the total number of healthy (diseased) patients.
It also appears to be more natural to deploy a Mon-
drian predictor rather than conformal predictor with
this taxonomy. This will be easily seen from the non-
conformity measure.
The nonconformity measure is calculated as follows.
We fix the number m of peaks used in a rule, so a
rule can include any m of M most frequent peaks. We
then consider a set of possible linear rules of type (4)
where parameters of the rules can possess the following
6 Dmitry Devetyarov et al.
values: θ ∈ R, vk ∈ Vk ⊆ R, qk ∈ Qk ⊆ {1, . . . ,M},
k = 1, . . . ,m.
We compare quality of rules by maximum of sen-
sitivity and specificity, in order not to improve one of
them by cost of other. In other terms, it can be said that
we are looking at the intersection of the ROC curve with
the diagonal.
Out of these rules we select the following one:
{v˜1, . . . , v˜m, θ˜, q˜1, . . . , q˜m}
= arg max
v1∈V1,...,vm∈Vm,
q1∈Q1,...,qm∈Qm
θ∈R
(min(TPR(v1, . . . , vm, θ, q1, . . . , qm),
TNR(v1, . . . , vm, θ, q1, . . . , qm))) , (5)
where
TPR(v1, . . . , vm, θ, q1, . . . , qm)
and
TNR(v1, . . . , vm, θ, q1, . . . , qm)
are sensitivity (true positive rate) and specificity (true
negative rate) of rule (4) with parameters
(v1, . . . , vm, θ, q1, . . . , qm),
respectively, on the set of patients including a new pa-
tient with a new hypothetical diagnosis. If there are
more than one set of parameters which provide maxi-
mum of the argmax expression, we choose the one with
the smallest absolute values of parameters giving prior-
ities in the following order: v1, . . . , vm, q1, . . . , qm, θ.
We can then define the nonconformity score of a new
patient with a candidate diagnosis on the basis of the
chosen rule. The value of the chosen linear combination∑m
k=1 v˜k log I(q˜k) is used as a nonconformity score for
healthy patients or as a value negative to a nonconfor-
mity score for diseased patients. Thus, when calculat-
ing a p-value, we compare the value of the chosen linear
combination for the new patient with the value of the
same combination for patients with the same diagnosis.
If a new patient was healthy, the larger the value of the
linear combination, the more nonconformal the patient
is, and the other way around if a patient is diseased.
Note that a rule itself reflects a hypothesis about
biomarkers relevant for diagnosis and their relative weight.
Therefore the algorithm includes a kind of embedded
feature (biomarker) selection.
In our experiments, the significance level is the same
for the classes of healthy and diseased patients. Leave-
one-out cross-validation is performed: each patient (xi, yi)
is considered as if it was a new test sample, and all the
remaining patients in the data are treated as the train-
ing set.
Algorithm 1Mondrian predictor based on linear rules
Require:
(x1, y1), . . . , (xn−1, yn−1) — sequence of patients with di-
agnoses, xi = {xi(1), . . . , xi(M)}, yi ∈ {0, 1}
xn — patient without a diagnosis
xi(j) — intensity of the peak j for the patient i
m — number of peaks in a linear rule
Vk ⊆ R, k = 1, . . . ,m — set of possible weights in linear
rules
Qk ⊆ {1, . . . ,M}, k = 1, . . . ,m — set of possible peak num-
bers in linear rules
for all y ∈ {0, 1} do
yn := y
zn := (xn, y)
for i := 1, . . . , n such that yi = y do
for v1 ∈ V1 do
for q1 ∈ Q1 do
. . .
for vm ∈ Vm do
for qm ∈ Qm do
Θ = {−∞} ∪ {Pmk=1 vk log xj(qk), j =
1, . . . ,m}
for θ ∈ Θ do
Compute predictions yˆj , j = 1, . . . , n,
provided by a linear rule with parame-
ters (v1, . . . , vm, θ, q1, . . . , qm):
for j := 1, . . . , n do
if
Pm
k=1 vk log xj(qk) > θ then
yˆj := 1
else
yˆj := 0
end if
end for
TPR(v1, . . . , vm, θ, q1, . . . , qm)
:=
|j=1,...,n: yj=1 & yˆj=yj |
|j=1,...,n: yj=1|
TNR(v1, . . . , vm, θ, q1, . . . , qm)
:=
|j=1,...,n: yj=0 & yˆj=yj |
|j=1,...,n: yj=0|
end for
end for
end for
end for
. . .
end for
{v˜1, . . . , v˜m, θ˜, q˜1, . . . , q˜m} :=
argmaxv1∈V1,...,vm∈Vm,
q1∈Q1,...,qm∈Qm
θ∈R
(min(TPR(v1, . . . , vm, θ, q1, . . . , qm),
TNR(v1, . . . , vm, θ, q1, . . . , qm)))
if y = 0 then
αi :=
Pm
k=1 v˜k log xn(q˜k)
else
αi := −
Pm
k=1 v˜k log xn(q˜k)
end if
end for
pn(y) :=
|{i=1,...,n−1: yi=y & αi≥αn}|+1
|{i=1,...,n−1: yi=y}|+1
end for
Compute a diagnosis for xn: ypred := argmaxy∈{0,1} pn(y)
Compute its confidence as 1−miny∈{0,1} pn(y)
Compute its credibility as maxy∈{0,1} pn(y)
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5 Results
5.1 Early detection
It is shown10 that for the analysed diseases there are
certain time slots when MS profile peaks carry statisti-
cally significant information for discrimination between
controls and cases, i.e., we can reject the null hypothe-
sis that the diagnosis is independent of the information
contained in peak intensities at significance level of 5%
well in advance of the moment of diagnosis.
In order to investigate how long in advance of the
moment of diagnosis accurate predictions can be pro-
vided, we consider different time slots of fixed length
(6 months for ovarian cancer and 12 months for breast
cancer) shifting away from the moment of diagnosis.
These time slots finish 1, 2, 3, . . .months in advance of
the moment of diagnosis.
After fixing the time slot, we pick all the patients
whose measurements were taken in this time slot to-
gether with matched controls. For the ovarian cancer
data, if several measurements of the same patients fall
in this time slot, we consider only the one closest to
the moment of the diagnosis, eliminating the others to-
gether with corresponding controls.
We then apply designed Mondrian predictors to pa-
tient measurements in time slots moving away from the
moment of the diagnosis. We expect prediction accu-
racy to deteriorate as the time slot is moving away since
we assume that, further from the moment of diagnosis,
mass spectra contain less information useful for discrim-
ination between cases and controls.
5.2 Ovarian Cancer Results
For the ovarian cancer data, we consider the simplest
possible combinations (4) of CA125 and one peak (m =
2); q1 corresponds to CA125 level (Q1 = {M}), Q2 =
{1, . . . ,M}, v1 ∈ V1 = {0, 0.5, 1, 2} is a CA125 weight,
v2 ∈ V2 = {−1, 0, 1} is a peak weight. V1 and V2 were se-
lected same as analogous parameters in our experiments
related to our previous works8,10. Our experience had
shown that because of the small number of samples,
any additional terms in the rules (4) are either useless
or would bring overfitting.
At first, we will demonstrate how prediction with
confidence works. For each patient, Mondrian predictor
provides two p-values, corresponding to ’healthy’ and
’diseased’ hypotheses. On the basis of these p-values, we
calculate confidence and credibility for each patient as
described in Section 2.1. After assigning every patient
with two p-values, we predict the diagnosis with the
highest p-value.
Table 1 represents several examples of p-values, con-
fidence and credibility for ovarian cancer measurements
taken not earlier than 6 months in advance of the mo-
ment of diagnosis. If confidence is close enough to 1 and
credibility is not close to 0, the prediction is considered
to be reliable.
We will demonstrate this in detail on several exam-
ples from Table 1. The columns represent a measure-
ment ID, true diagnosis, predicted diagnosis, p-values
for ‘healthy’ and ‘diseased’ diagnoses, confidence and
credibility. For instance, patient with measurement ID
141100 in Table 1 has two p-values one of which is close
to 1 (0.99), another — close to 0 (0.01). This results
in high confidence of 0.99 and high credibility of 0.99
and identifies the prediction as reliable: only one di-
agnosis conforms well the rest of the set. If this pa-
tient was classified as a case (diagnosis value of 1),
this would mean that an event of probability ≤ 1%
occurred. For this reason, we expect the patient to be
healthy, which is correct. In contrast, patient with mea-
surement ID 146384 has low p-values close to each other
(0.12 and 0.13), which means neither of the diagnoses is
likely to be correct and, hence, there is not enough infor-
mation to confidently classify the patient. Thus, these
p-values do not produce confidence close enough to 1
(0.88) or high credibility (0.13). As a result, the output
prediction for the patient with measurement ID 146384
is indeed incorrect.
Table 2 shows the accuracy of Mondrian predic-
tors in different time slots. The table demonstrates that
Mondrian predictors are reasonably accurate well in ad-
vance of the moment of diagnosis. For example, the ac-
curacy in the time slot of 10–16 months (the latest time
slot when CA125 on its own does not carry statistically
significant information for disease discrimination8) is
70.2%. This is quite good given that diagnosis is made
not later than 10 months in advance before the diagno-
sis is confirmed by histology/cytology. For comparison,
when we make predictions with the same method of
measurements just before the moment of diagnosis (in
a 0–6 time slot), the accuracy is equal to 92.2%.
When we combine results for different time slots, we
can estimate how Mondrian predictors perform in early
ovarian cancer diagnosis. In general, Mondrian predic-
tors produce predictions with accuracy higher than 66%
up to 11 months in advance of the moment of diagnosis.
As we move away from the moment of diagnosis, accu-
racy of predictions decreases. Low accuracy 6, 7 and 8
months in advance may be explained by a small num-
ber of samples in this period (below 70 samples for any
time slot).
To estimate statistical significance of achieved ac-
curacy, we calculated p-values that reject the null hy-
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pothesis that the assignment of labels is independent
of MS peak intensities and CA125 levels. The p-values
we calculated by the use of the Monte-Carlo method:
we estimate how possible it is to make the prediction of
same quality by chance. Suppose there is no real depen-
dence between true diagnosis and peak intensities. Such
a situation can be simulated by reshuﬄe of the labels
without changing the feature information. Monte-Carlo
method answers the questions: what will be the accu-
racy in this case? In what percentage of cases it will
be as good as the current one or even better? For each
time slot, we consider Mondrian predictor’s accuracy.
For a large number N = 500 of times, we calculate
the statistics, the accuracy of the Mondrian predictor
applied to the data in the same time slot but with ran-
domly permuted labels. Accuracy here is just amount
of true diagnoses. We count a number of times n when
the statistics is at least as high as the accuracy cal-
culated on true labels. The p-value is then defined as
(n+ 1)/(N + 1).
These p-values are presented in the last column of
Table 2, which shows that the accuracy achieved in the
time slots finishing 0–6 and 9–11 months in advance is
significant at the level of 5%. Analogous p-values were
calculated for linear combinations of CA125 and MS
peaks without the framework of Mondrian predictors.
We obtained values similar to the ones calculated for
Mondrian predictors. In particular, p-values were below
5% in the same time slots, which demonstrates that
CA125 and MS peaks carry information which allows
statistically significant discrimination between ovarian
cancer patients and controls.
As mentioned before, the feature of the ovarian can-
cer data set is that ovarian cancer cases can have several
measurements taken at different moments. For this rea-
son, we can observe the change in the output of Mon-
drian predictors for this data set. As an illustration,
we will consider several ovarian cancer cases that have
measurements taken over a long period of time and will
show how confidence and credibility are changing when
the patient is approaching the moment of diagnosis.
We select patients with at least three measurements.
For each measurement, we train the Mondrian predic-
tor on the samples in the earliest 6-month time slot
containing the measurement leaving out the measure-
ment itself. For example, if a measurement was taken
6.5 months in advance, we consider the time slot from
month 12 to month 6. We then apply the Mondrian
predictor to the left-out measurement and output a
prediction, its confidence and credibility. Dynamics of
confidence and credibility for measurements of several
patients is shown in Table 3.
We can trust the prediction if its confidence is close
to 1 (i.e., all p-values for alternative diagnoses are close
to 0) and its credibility is not close to 0 (i.e., the max-
imum p-value is not close to 0). This implies that if
a Mondrian predictor makes correct predictions about
the case, we expect confidence to be approaching 100%
when measurements are getting closer to the moment
of diagnosis. Meanwhile, credibility is expected not to
be getting close to 0%. Table 3 demonstrates that pa-
tient 39 confirms our expectations.
Patient 42 represents a more interesting example:
we make an erroneous prediction 15 months in advance.
However, its confidence is not close to 100%, which re-
flects that we cannot be sure in this prediction. When
we make a final prediction for this patient 3 months
in advance, both confidence and credibility are close to
100%.
Overall statistic of conformal predictor output in
terms of prediction sets is presented in the Table 7.
It shows that number of certain predictions (for which
prediction set consists of only one label) increases for
ovarian cancer as time becomes closer to diagnosis.
5.3 Breast Cancer Results
The same approach was applied to the set of breast
cancer patients and matched controls, which was taken
from the UKCTOCS trial. We consider cut-off rules (4)
with one peak involved (m = 1) with Q1 = {1, . . . ,M}
and v1 ∈ V1 = {−1, 1}, a weight that determines whether
the peak has higher or lower intensities for cases.
Firstly, this approach allows us to complement each
diagnosis of prediction with measures of confidence and
credibility. This is demonstrated in Table 4, which con-
tains p-values, confidence and credibility for some breast
cancer and healthy patients whose measurements were
taken no earlier than 12 months in advance of the mo-
ment of diagnosis.
Secondly, Mondrian predictors result in accurate pre-
dictions well in advance of the moment of diagnosis
(detailed results are presented in Table 5). Mondrian
predictors achieve an accuracy higher than 70% up to
9 months in advance of the moment of breast cancer di-
agnosis. However, there is no apparent decreasing trend
in accuracy; it fluctuates in the range of 70.4–77.8%. It
falls to 71.9% in the latest time slot (0–12 months) be-
cause number of examples have suddenly fallen to 57.
At slot (10–22 months) it falls to 48.2%, this is be-
cause selection if best rule become unstable: according
to the table 6, top peak 19 is selected only in 87%,
so selection is not robust even to change of one exam-
ple. Monte-Carlo p-values shown in the last column of
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Table 5 demonstrate statistical significance of achieved
accuracy up to 8 months in advance of the moment of
diagnosis.
5.4 Informative peaks and comparison to related
research
In parallel, another approach was applied to the UKC-
TOCS data sets in another paper8, which is written
from the medical point of view and utilises already de-
veloped methods of early diagnosis and peak identifi-
cation. The research is devoted to statistical analysis,
whereas this paper describes machine learning approach
that complements each prediction with its confidence.
In addition, statistical analysis was carried out in a
different experimental setting: the data were normal-
ized against such factors as age, sample collection time
and location, storage and transportation conditions. All
measurements were grouped in triplets comprising one
diseases patient and two healthy controls matched by
these factors. Thus, when making predictions, we had
additional information about diagnosis distribution: we
knew that exactly one patient was diseased in a triplet.
We will refer to this research and the corresponding pa-
per as triplet analysis. Triplet analysis pinpointed MS
profile peaks that allowed statistically significant (con-
taining essential information in addition to CA125) dis-
crimination at the 5% level between cases and controls
long in advance of the moment of diagnosis of ovarian
cancer. We demonstrated that mass spectra from the
low molecular weight serum proteome carry informa-
tion useful for early detection.
The triplet analysis8 of the ovarian and breast can-
cers allowed us to determine statistically significant peaks
which could be potential candidates for biomarkers. We
identified certain MS profile peaks that carry statisti-
cally significant information for the diagnosis of the dis-
eases. In the current research we do not analyse statisti-
cal significance of particular peaks. However, Mondrian
predictors indirectly pinpointed informative peaks. De-
spite the different nature of these methods, observed
mostly the same peaks as the ones that carry statisti-
cally significant information for discrimination between
controls and cases according to the triplet analysis.
We will consider the time slots when Mondrian pre-
dictors produced high accuracy on the data sets. In ad-
dition, for ovarian cancer, we are especially interested
in time slots starting from month 10 because this is
the first time slot when CA125 on its own does not
provide statistically significant discrimination between
cases and controls.
Mondrian predictors help us identify informative peaks
in the following way. When we run leave-one-out pro-
cedure, for each possible diagnosis we choose the best
rule w log(C) + v log I(p) > θ (for ovarian cancer) or
v log I(p) > θ (for breast cancer), which contains a
peak. The selected peak may not be the same for every
possible diagnosis and every possible left out patient,
but in the time slots we are examining, the same peak
was selected as a part of the best rule, that is, we choose
the same weights and peak number when leaving out a
patient: these are peak 19 for breast cancer in time slots
finishing with months 0–9, 11, 12 and peak 3 for ovar-
ian cancer in time slots finishing with months 9–11. The
detailed results for ovarian and breast cancer measure-
ments taken in different time slots are represented in
Table 6. The table shows the peak which was selected
most often (‘Top peak’) and how often it was selected
(‘Peak frequency’).
Table 8 summarizes all peaks selected by two dif-
ferent approaches: triplet analysis and Mondrian pre-
dictors. Those peaks are shown that were selected in
time slots of high interest: slots finishing with months
0–9 for breast cancer and 10–11 for ovarian cancer. Ta-
ble 8 demonstrates that Mondrian predictors pinpoint
the same peaks as identified as carrying statistically
significant information in the triplet setting.
For the ovarian cancer data, both methods select
peak 3 in time slots finishing with month 10 or 11.
These are the time slots when CA125 on its own does
not carry statistically significant information as shown
in the triplet analysis8. Ovarian cancer peak 3 was also
observed in research on other data sets11. In addition,
peak 3 coincides with peak 7 previously found in the
analysis of similar serial ovarian cancer samples and
controls in the pilot10,12 trial which preceded UKC-
TOCS. Peak 3 is identified as CTAP III13 and peak
2 is is potentially platelet factor 4 (PF4).
The predictive ability of CA125 on its own and in
combination with peak 3 is demonstrated in Figure 2.
The figure illustrates that the combination of CA125
with peak 3 starts growing earlier than logC; CA125
growth at the moments close to diagnosis is quicker due
to the exponential growth of CA125. Graphs with simi-
lar behaviour for a combination of CA125 with another
peak were presented in the pilot10 trial.
For the breast cancer data, we observe the dynamics
of selected peak 19, whose intensities are supposed to
be lower for cases rather than for controls according to
our research. In Figure 3, the solid line represents the
median dynamics of peak 19 for breast cancer cases, the
dashed line shows the peak 19 median calculated for all
breast cancer controls. The values in the figure were
calculated for measurements within a 9-month window
ending with the month shown on the horizontal axis.
One can see from Figure 3 that peak 19 median inten-
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Fig. 2 Median dynamics of intensity for rules logCA125 and
logCA125− log(Peak 3) (for ovarian cancer cases only)
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Fig. 3 Median dynamics of intensity for peak 19 in the breast
cancer data for cases and the median of peak 19 for controls
sity drops about 15 months in advance of the moment
of the diagnosis, which confirms our hypothesis about
predictive ability of peak 19 and explains the results we
obtained using this peak when discriminating between
breast cancer cases and controls. Peak 19 is preliminary
identified as either ApoCI or ApoCII (or their combi-
nation).
6 Discussion
This paper introduced the methodology of providing
predictions with confidence for MS-based proteomics.
First, the framework of Mondrian predictors allowed us
to complement each prediction with certain informa-
tion reflecting our confidence in each prediction. Sec-
ond, application of Mondrian predictors to the ovar-
ian and breast cancer experimental data demonstrated
that Mondrian predictors result in high accuracy well
in advance of the moment of the disease diagnosis. The
accuracy of the proposed methods on the ovarian can-
cer data rises from 66.7% 11 months in advance of the
moment of diagnosis to up to 92.2% just before the mo-
ment of diagnosis. When applied to the breast cancer
data, the methods allowed us to achieve accuracy of
70.4–77.8% for up to 9 months in advance of diagnosis.
We constructed a special NCM in order to take into
account data specific nature (mass spectrometry) and
additional aim (biomarker identification). However, it
might be too straightforward in the part of search: we
used overall scanning within the set of possible rules.
It was done in order to make general idea more clear,
but it may be one of future tasks to replace it with a
more practical way of search. Also, we assumed that
only few biomarkers might be informative for the pre-
diction. Alternative to this is a possible influence of
the disease on many peaks in larger or smaller degree,
search methods as SVM are more relevant here as there
are less restrictions on the rule set. But in this case a
clear interpretation of results (list of found biomarkers)
becomes more complex task.
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Table 1 Examples of the output of Mondrian predictors ap-
plied to the ovarian cancer data in a 0–6 month time slot: true
and predicted diagnoses, p-values for both diagnoses, confi-
dence and credibility for several patients
Meas. True Pred. p-value p-value Conf. Cred.
ID diagn. diagn. for 0 for 1
141100 0 0 0.99 0.01 0.99 0.99
146384 0 1 0.12 0.13 0.88 0.13
232604 1 0 0.51 0.28 0.72 0.51
245401 1 1 0.01 0.97 0.99 0.97
Table 2 Accuracy of Mondrian predictors applied to the
ovarian cancer data set (CA125 and 5 most frequent peaks)
in the leave-one-out mode in different time slots
Time slot Samples Accuracy Sensitivity Specificity p-value
0–6 204 92.2% 91.2% 92.7% 0.002
1–7 168 89.9% 89.3% 90.2% 0.002
2–8 141 83.7% 83.0% 84.0% 0.002
3–9 108 78.7% 80.6% 77.8% 0.002
4–10 81 79.0% 74.1% 81.5% 0.002
5–11 69 73.9% 73.9% 73.9% 0.002
6–12 60 66.7% 65.0% 67.5% 0.050
7–13 51 68.6% 64.7% 70.6% 0.060
8–14 51 66.7% 70.6% 64.7% 0.102
9–15 60 73.3% 75.0% 72.5% 0.020
10–16 84 70.2% 71.4% 69.6% 0.004
11–17 84 66.7% 67.9% 66.1% 0.050
Table 3 Dynamics of confidence and credibility for measure-
ments taken for two ovarian cancer cases
Case ID Months in advance Prediction Confidence Credibility
39 10 1 89.5% 67.9%
4 1 90.9% 44.4%
2 1 99.0% 66.0%
1 1 99.1% 76.8%
42 24 1 69.0% 71.4%
15 0 45.0% 78.1%
3 1 98.6% 100.0%
Table 4 The output of Mondrian predictors applied to the
breast cancer data in the time slot of 0–12 months in ad-
vance: true and predicted diagnoses, p-values for both diag-
noses, confidence and credibility form some patients
Measurement True Predicted p-value p-value Confidence Credibility
ID diagnosis diagnosis for 0 for 1
1832 0 1 0.29 0.30 0.71 0.30
77217 0 0 1.00 0.05 0.95 1.00
195604 1 1 0.08 0.95 0.92 0.95
Table 5 Accuracy of Mondrian predictors applied to the
breast cancer data set (20 most frequent peaks) in the leave-
one-out mode in different time slots
Time slot Number of samples Accuracy Sensitivity Specificity p-value
0–12 57 71.9% 73.7% 71.1% 0.028
1–13 72 77.8% 79.2% 77.1% 0.002
2–14 78 76.9% 76.9% 76.9% 0.002
3–15 78 76.9% 76.9% 76.9% 0.002
4–16 72 77.8% 79.2% 77.1% 0.002
5–17 72 75.0% 75.0% 75.0% 0.002
6–18 60 73.3% 75.0% 72.5% 0.012
7–19 57 71.9% 73.7% 71.1% 0.040
8–20 51 70.6% 70.6% 70.6% 0.026
9–21 54 70.4% 72.2% 69.4% 0.066
10–22 54 48.2% 55.6% 44.4% 0.535
11–23 54 70.4% 72.2% 69.4% 0.058
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Table 6 Top peaks pinpointed by Mondrian predictors in
different time slots for the ovarian and breast cancer data
sets
Month Ovarian cancer Breast cancer
Top Peak Top Peak
peak frequency peak frequency
0 1 96.1% 19 100.0%
1 1 83.0% 19 100.0%
2 1 72.7% 19 100.0%
3 2 56.0% 19 100.0%
4 2 98.2% 19 100.0%
5 1 95.7% 19 100.0%
6 1 69.2% 19 100.0%
7 4 94.1% 19 100.0%
8 3 73.5% 19 100.0%
9 3 100.0% 19 100.0%
10 3 100.0% 19 87.0%
11 3 100.0% 19 100.0%
12 2 85.7% 19 100.0%
13 3 95.0% 6 78.4%
14 3 85.3% 15 100.0%
15 2 89.2% 14 67.5%
16 5 63.3% 14 67.5%
Table 7 The certainty rate of prediction output by category-
based confidence machines at significance levels  =
5%, 10%, 20% in different time slots for the ovarian cancer
and breast cancer data sets.
Time Ovarian cancer Breast cancer
slot  = 5%  = 10%  = 20%  = 5%  = 10%  = 20%
0–6 91.7% 94.1% 81.4% 5.3% 15.8% 50.9%
1–7 78.6% 94.6% 84.5% 8.3% 23.6% 62.5%
2–8 58.2% 80.1% 90.1% 7.7% 24.4% 76.9%
3–9 25.9% 48.2% 88.9% 7.7% 24.4% 76.9%
4–10 27.2% 56.8% 91.4% 8.3% 19.4% 93.1%
5–11 21.7% 44.9% 71.0% 8.3% 29.2% 88.9%
6–12 18.3% 41.7% 58.3% 10.0% 36.7% 90.0%
7–13 9.8% 21.6% 62.8% 5.3% 14.0% 59.7%
8–14 2.0% 29.4% 60.8% 3.9% 17.7% 62.8%
9–15 18.3% 33.3% 73.3% 1.9% 14.8% 64.8%
10–16 11.9% 29.8% 67.9% 1.9% 14.8% 35.2%
11–17 9.5% 22.6% 58.3% 1.9% 16.7% 50.0%
Table 8 Numbers of the most important peaks selected with
different methods for the ovarian and breast cancer data sets
Method Ovarian cancer Breast cancer
Triplet analysis 2, 3 19
Mondrian predictors 3 19
